Mankind Pharma promoters and promoter group have confirmed that no encumbrance was made on the shares held by them during the financial year ended March 31, 2026. The disclosure was submitted to the stock exchanges pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The confirmation is intended to inform shareholders and regulatory bodies about the status of the promoters' holdings.

The filing, dated April 07, 2026, was signed by Ramesh Juneja, Promoter of Mankind Pharma Limited. It explicitly states that neither the promoters nor the promoter group, along with persons acting in concert, have created any direct or indirect encumbrance on their shareholdings in the company during FY26. This compliance ensures transparency regarding the leverage or pledging of promoter shares, a key metric for investor risk assessment.

The disclosure includes a comprehensive list of 89 entities categorized as promoters, promoter group, and persons acting in concert. The list details the specific individuals, family trusts, and corporate entities that fall under these classifications.

List of Promoters

Promoter Group Entities

The promoter group comprises 83 additional entities, including family members, HUFs, and various private limited companies and LLPs. Notable entities within the promoter group include Poonam Juneja, Arjun Juneja, and corporate entities such as Mankind Biotech Private Limited, Pathkind Diagnostics Private Limited, and Bestochem Formulations (India) Limited. The full list of 89 entities is attached as Annexure-1 to the regulatory filing.

Mankind Pharma Limited has appointed Mr. Nilesh Kulkarni as the Head of Human Resource Functions for the Group and designated him as a Senior Management Personnel (SMP), effective June 8, 2026. This strategic realignment of the human resources leadership framework was approved by the Board of Directors through a resolution passed by circulation as part of an internal organizational restructuring. Consequently, Mr. Prateek Dubey has ceased to be a Senior Management Personnel as he transitions to new roles and responsibilities.

Mr. Nilesh Kulkarni brings over 25 years of experience as a senior HR professional, specializing in organizational transformation and high-performance cultures within the pharmaceutical sector. His expertise includes multi-country M&A, integrations, learning and development architecture, talent management, succession planning, and complex organization design across India and international markets. He has held leadership positions in India, South Asia, and Europe.

Prior to this appointment, Mr. Kulkarni spent over six years as the Chief Human Resources Officer (CHRO) of Bharat Serums and Vaccines Ltd. (BSV), a material wholly owned subsidiary of the Company. He has previously been associated with Novo Nordisk, Roche, Novartis, and Sanofi. The appointment is full-time and governed by the standard policies and service rules of the Company.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that Mr. Nilesh Kulkarni and Mr. Prateek Dubey do not have any relationship with the Directors of the Company.

Key Appointments and Changes